Header Logo

Connection

JAMES P ALLISON to Pyrimidinones

Back to Details
This is a "connection" page, showing publications JAMES P ALLISON has written about Pyrimidinones.
JAMES P ALLISON
Connection Strength
0.129
Pyrimidinones
  1. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.129
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.